Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Source filing unavailable
Q1 2014 · —
Revenue$215.06M$215.06M+9.4% vs Q1 2013 Net Income$2.21M$2.21MN/M vs Q1 2013 EPS Diluted$0.07$0.07N/M vs Q1 2013 Gross Profit$112,556,000−3.8% Operating Income$8,738,000N/M Operating Cash Flow$11,254,000
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
+43.4%
Free Cash Flowderived-$81,000N/M Margins · derivedGross margin52.3%−7.2 pt vs Q1 2013
Operating margin4.1%+5.2 pt vs Q1 2013
Net margin1.0%+4.1 pt vs Q1 2013